Ex-Bioverativ CEO John Cox lands at Torque Therapeutics by Amirah Al Idrus Wednesday, October 2, 2019 John Cox, who led Bioverativ through its $11.6 billion Sanofi buyout, is helming Torque, which is working on "deep-primed" T-cell therapies for cancer.
